Variability of Lung Tumor Measurements on Repeat Computed Tomography Scans Taken Within 15 Minutes von OXNARD, Geoffrey R, BINSHENG ZHAO, SIMA, Camelia S, GINSBERG, Michelle S, JAMES, Leonard P, LEFKOWITZ, Robert A, PINGZHEN GUO, KRIS, Mark G, SCHWARTZ, Lawrence H, RIELY, Gregory J

Volltext

Editorial Commentary: A Complex Network of Bony and Soft-Tissue Stabilizers—and Overall Limb Alignment—Determines Patellofemoral Stability von Leonard, James P

Volltext

THE MYC/MAX/MAD NETWORK AND THE TRANSCRIPTIONAL CONTROL OF CELL BEHAVIOR von Grandori, Carla, Cowley, Shaun M, James, Leonard P, Eisenman, Robert N

Volltext

Editorial Commentary: Preoperative Exercise, Workers' Compensation, Diabetes, Lateral Extra-Articular Tenodesis, and Return to Sport Determine Patient Satisfaction After Anterior C... von Leonard, James P.

Volltext

Lorlatinib in non-small-cell lung cancer with ALK or ROS1 rearrangement: an international, multicentre, open-label, single-arm first-in-man phase 1 trial von Shaw, Alice T, Felip, Enriqueta, Bauer, Todd M, Besse, Benjamin, Navarro, Alejandro, Postel-Vinay, Sophie, Gainor, Justin F, Johnson, Melissa, Dietrich, Jorg, James, Leonard P, Clancy, Jill S, Chen, Joseph, Martini, Jean-François, Abbattista, Antonello, Solomon, Benjamin J

Volltext

Editorial Commentary: My Harvested Hamstring Autograft Is Too Small. Now What? von Leonard, James P

Volltext

Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study von Solomon, Benjamin J, Besse, Benjamin, Bauer, Todd M, Felip, Enriqueta, Soo, Ross A, Camidge, D Ross, Chiari, Rita, Bearz, Alessandra, Lin, Chia-Chi, Gadgeel, Shirish M, Riely, Gregory J, Tan, Eng Huat, Seto, Takashi, James, Leonard P, Clancy, Jill S, Abbattista, Antonello, Martini, Jean-François, Chen, Joseph, Peltz, Gerson, Thurm, Holger, Ou, Sai-Hong Ignatius, Shaw, Alice T

Volltext

Resensitization to Crizotinib by the Lorlatinib ALK Resistance Mutation L1198F von Shaw, Alice T, Friboulet, Luc, Leshchiner, Ignaty, Gainor, Justin F, Bergqvist, Simon, Brooun, Alexei, Burke, Benjamin J, Deng, Ya-Li, Liu, Wei, Dardaei, Leila, Frias, Rosa L, Schultz, Kate R, Logan, Jennifer, James, Leonard P, Smeal, Tod, Timofeevski, Sergei, Katayama, Ryohei, Iafrate, A. John, Le, Long, McTigue, Michele, Getz, Gad, Johnson, Ted W, Engelman, Jeffrey A

Volltext

Lorlatinib Exposure‐Response Analyses for Safety and Efficacy in a Phase I/II Trial to Support Benefit–Risk Assessment in Non‐Small Cell Lung Cancer von Chen, Joseph, Ruiz‐Garcia, Ana, James, Leonard P., Peltz, Gerson, Thurm, Holger, Clancy, Jill, Hibma, Jennifer

Volltext

Response to “Lorlatinib Exposed: A Far from Optimal Dose” von Chen, Joseph, Ruiz‐Garcia, Ana, James, Leonard P., Peltz, Gerson, Thurm, Holger, Clancy, Jill, Hibma, Jennifer

Volltext

Evaluating variability in tumor measurements from same-day repeat CT scans of patients with non-small cell lung cancer von Zhao, Binsheng, James, Leonard P, Moskowitz, Chaya S, Guo, Pingzhen, Ginsberg, Michelle S, Lefkowitz, Robert A, Qin, Yilin, Riely, Gregory J, Kris, Mark G, Schwartz, Lawrence H

Volltext

The Effect of Rifampin on the Pharmacokinetics and Safety of Lorlatinib: Results of a Phase One, Open-Label, Crossover Study in Healthy Participants von Chen, Joseph, Xu, Huiping, Pawlak, Sylvester, James, Leonard P., Peltz, Gerson, Lee, Kimberly, Ginman, Katherine, Bergeron, Michelle, Pithavala, Yazdi K.

Volltext

Combined Pan-HER and ALK/ROS1/MET Inhibition with Dacomitinib and Crizotinib in Advanced Non–Small Cell Lung Cancer: Results of a Phase I Study von Jänne, Pasi A., Shaw, Alice T., Camidge, D. Ross, Giaccone, Giuseppe, Shreeve, S. Martin, Tang, Yiyun, Goldberg, Zelanna, Martini, Jean-François, Xu, Huiping, James, Leonard P., Solomon, Benjamin J.

Volltext

Correction to: The Effect of Rifampin on the Pharmacokinetics and Safety of Lorlatinib: Results of a Phase One, Open-Label, Crossover Study in Healthy Participants von Chen, Joseph, Xu, Huiping, Pawlak, Sylvester, James, Leonard P., Peltz, Gerson, Lee, Kimberly, Ginman, Katherine, Bergeron, Michelle, Pithavala, Yazdi K.

Volltext

Do Newer-Generation Bioabsorbable Screws Become Incorporated into Bone at Two Years After ACL Reconstruction with Patellar Tendon Graft?: A Cohort Study von Cox, Charles L, Spindler, Kurt P, Leonard, James P, Morris, Brent J, Dunn, Warren R, Reinke, Emily K

Volltext

A phase 2 study of weekly albumin-bound paclitaxel (Abraxane®) given as a two-hour infusion von Paik, Paul K., James, Leonard P., Riely, Gregory J., Azzoli, Christopher G., Miller, Vincent A., Ng, Kenneth K., Sima, Camelia S., Heelan, Robert T., Kris, Mark G., Moore, Erin, Rizvi, Naiyer A.

Volltext

T1165 Use of Newer Agents in the Treatment of Gastric Adenocarcinoma von Somnay, Kaumudi, Kumar, Sandeep, James, Leonard P, Kaplan, Barry H

Volltext

Evaluating Variability in Tumor Measurements from Same-day Repeat CT Scans of Patients with Non―Small Cell Lung Cancer1 von BINSHENG ZHAO, JAMES, Leonard P, MOSKOWITZ, Chaya S, PINGZHEN GUO, GINSBERG, Michelle S, LEFKOWITZ, RobertA, YILIN QIN, RIELY, GregoryJ, KRIS, Mark G, SCHWARTZ, Lawrence H

Volltext

The Effect of Rifampin on the Pharmacokinetics and Safety of Lorlatinib: Results of a Phase One, Open-Label, Crossover Study in Healthy Participants (vol 37, pg 745, 2020) von Chen, Joseph, Xu, Huiping, Pawlak, Sylvester, James, Leonard P., Peltz, Gerson, Lee, Kimberly, Ginman, Katherine, Bergeron, Michelle, Pithavala, Yazdi K.

Volltext

Lorlatinib Exposure-Response Analyses for Safety and Efficacy in a Phase 1/2 Trial to Support Benefit-Risk Assessment in Non-Small Cell Lung Cancer von Chen, Joseph, Ruiz-Garcia, Ana, James, Leonard P, Peltz, Gerson, Thurm, Holger, Clancy, Jill, Hibma, Jennifer

Volltext